Literature DB >> 21437578

Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.

Hitoshi Yokoyama1, Hiroshi Okuyama2, Hideki Yamaya2.   

Abstract

Lupus nephritis comprises a spectrum of glomerular, vascular, and tubulointerstitial lesions, which has significant racial variation in severity and manifestations. The current classification (ISN/RPS 2003) has been improved successfully for the categorization of lupus glomerulonephritis (LGN). On the basis of this classification, 480 Japanese cases revealed the following distribution: class I 3%, class II 16%, class III 13%, class IV-S 11%, class IV-G 41%, class V 16%, and class VI 1%. Class IV-G with chronicity tended to have the worst renal outcome. Nephrotic syndrome was a more frequent complication in class IV-S (50%), class IV-G (72%), and class V (56%), with poor renal and actuarial outcomes. With regard to therapy, treatment options including glucocorticoids alone or combined with antimetabolites (azathioprine, mizoribine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine A, tacrolimus), or alkylating agents (intravenous cyclophosphamide injection) improved the outcome of LGN; however, there is no high-grade clinical evidence from Japan. Further studies are needed to resolve the clinicopathological problems of LGN, especially IV-S, IV-G, and pure membranous lupus nephritis in Japanese patients.

Entities:  

Mesh:

Year:  2011        PMID: 21437578     DOI: 10.1007/s10157-011-0434-0

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  47 in total

1.  The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide.

Authors:  Naomi Matsuyama; Shinji Morimoto; Yoshiaki Tokano; Hirofumi Amano; Kazuhisa Nozawa; Hiroshi Isonuma; Hiroshi Hashimoto; Yoshinari Takasaki
Journal:  Intern Med       Date:  2010-04-30       Impact factor: 1.271

2.  Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins.

Authors:  H Arahata; K Migita; H Izumoto; T Miyashita; H Munakata; H Nakamura; M Tominaga; T Origuchi; Y Kawabe; A Hida; T Taguchi; K Eguchi
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 3.  Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden.

Authors:  N Danchenko; J A Satia; M S Anthony
Journal:  Lupus       Date:  2006       Impact factor: 2.911

4.  The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese.

Authors:  Hitoshi Yokoyama; Takashi Wada; Akinori Hara; Junya Yamahana; Izaya Nakaya; Motoo Kobayashi; Kiyoki Kitagawa; Satoshi Kokubo; Yasunori Iwata; Keiichi Yoshimoto; Kazuaki Shimizu; Norihiko Sakai; Kengo Furuichi
Journal:  Kidney Int       Date:  2004-12       Impact factor: 10.612

5.  Severe lupus nephritis: racial differences in presentation and outcome.

Authors:  Stephen M Korbet; Melvin M Schwartz; Joni Evans; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

6.  Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial.

Authors:  Yuriko Tanaka; Norishige Yoshikawa; Shinzaburo Hattori; Satoshi Sasaki; Takashi Ando; Masahiro Ikeda; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

7.  Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center.

Authors:  F Yu; Y Tan; L-H Wu; S-N Zhu; G Liu; M-H Zhao
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

8.  Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis.

Authors:  Shoichiro Kojo; Ken-ei Sada; Mizuho Kobayashi; Mie Maruyama; Yohei Maeshima; Hitoshi Sugiyama; Hirofumi Makino
Journal:  J Rheumatol       Date:  2009-07-31       Impact factor: 4.666

9.  Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.

Authors:  N Hiramatsu; T Kuroiwa; H Ikeuchi; A Maeshima; Y Kaneko; K Hiromura; K Ueki; Y Nojima
Journal:  Rheumatology (Oxford)       Date:  2008-04-04       Impact factor: 7.580

10.  Glomerular podocytopathy in patients with systemic lupus erythematosus.

Authors:  Steven W Kraft; Melvin M Schwartz; Stephen M Korbet; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2004-11-17       Impact factor: 10.121

View more
  5 in total

1.  Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hitoshi Yokoyama; Takashi Taguchi; Hitoshi Sugiyama; Hiroshi Sato
Journal:  Clin Exp Nephrol       Date:  2012-02-23       Impact factor: 2.801

Review 2.  Recent advances in the treatment of lupus nephritis.

Authors:  Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-11-08       Impact factor: 2.801

3.  Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.

Authors:  Maria Victoria Collado; Enrique Dorado; Silvia Rausch; Graciela Gomez; Marina Khoury; Federico Zazzetti; María Gargiulo; Lorena Suarez; Rafael Chaparro; Sergio Paira; Laura Galvan; Vicente Juarez; Cecilia Pisoni; Mercedes Garcia; Liliana Martinez; Analia Alvarez; Clarisa Alvarez; Juan Barreira; Judith Sarano
Journal:  J Clin Rheumatol       Date:  2016-09       Impact factor: 3.517

4.  Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.

Authors:  Liliana Michelle Gomez Mendez; Matthew D Cascino; Tamiko R Katsumoto; Paul Brakeman; Paul Brunetta; David Jayne; Maria Dall'Era; Brad Rovin; Jay Garg
Journal:  Lupus Sci Med       Date:  2019-02-04

5.  Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study.

Authors:  Min Feng; Jun Lv; Sha Fu; Bo Liu; Ying Tang; Xia Wan; Peifen Liang; Yuchun Zeng; Jingao Li; Yanying Lu; Xiaomei Li; Anping Xu
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.